alexa Survival and Determinants of Mortality in Adult HIV/AIDS Patients Initiating Antiretroviral Therapy in Somali Region, Eastern Ethiopia | Open Access Journals
ISSN 2155-6113
Journal of AIDS & Clinical Research
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Survival and Determinants of Mortality in Adult HIV/AIDS Patients Initiating Antiretroviral Therapy in Somali Region, Eastern Ethiopia

Bereket Damtew1*, Bezatu Mengistie2 and Tadesse Alemayehu2

1Department of Epidemiology and Biostatistics, College of Health and Medical Sciences, Haramaya University, Ethiopia

2Department of Public Health, College of Health and Medical Sciences, Haramaya University, Ethiopia

*Corresponding Author:
Bereket Damtew
Department of Epidemiology and Biostatistics
College of Health and Medical Sciences
Haramaya University, P.O. Box 1570
Harar, Ethiopia
Tel: 251911730383
E-mail: [email protected]

Received Date: May 17, 2014; Accepted Date: July 24, 2014; Published Date: July 30, 2014

Citation: Damtew B, Mengistie B, Alemayehu T (2014) Survival and Determinants of Mortality in Adult HIV/AIDS Patients Initiating Antiretroviral Therapy in Somali Region, Eastern Ethiopia. J AIDS Clin Res 5:327. doi:10.4172/2155-6113.1000327

Copyright: © 2014 Damtew B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of AIDS & Clinical Research


Background: Studies have shown high initial mortality in Antiretroviral Therapy (ART) programs from resource-limited settings. However, there is dearth of evidence on treatment outcomes and associated determinant factors in public hospitals. Therefore, the objective of this study is to assess survival and identify predictors of death in adult HIV-infected patients initiating ART at a public hospital in Eastern Ethiopia.

Methods: A retrospective cohort study was conducted by reviewing baseline and follow-up records of patients who started ART between December 1, 2007 and December 31, 2011 at Kharamara hospital. Time to death was the main outcome measure. Kaplan- Meier models were used to estimate mortality and Cox proportional hazards models to identify predictors of mortality.

Results: A total of 784 patients (58.4% females) were followed for a median of 60 months. There were 87 (11.1%) deaths yielding an overall mortality rate of 5.15/100 PYO (95% CI: 4.73-6.37). The estimated mortality was 8.4%, 9.8%, 11.3%, 12.7% and 14.1% at 6, 12, 24, 36 and 48 months respectively. The independent predictors of death were single marital status (AHR: 2.31; 95%CI: 1.18-4.50), a bedridden functional status (AHR: 5.91; 95%CI: 2.87-12.16), advanced WHO stage (AHR: 7.36; 95%CI: 3.17-17.12), Body Mass Index (BMI)< 18.5 Kg/m2 (AHR: 2.20; 95%CI: 1.18-4.09), CD4 count < 50 cells/μL (AHR: 2.70; 95%CI: 1.26-5.80), severe anemia (AHR: 4.57; 95%CI: 2.30-9.10), and Tuberculosis (TB) co-infection (AHR: 2.30; 95%CI: 1.28-4.11).

Conclusion: Improved survival was observed in patients taking ART in Somali region of Ethiopia. The risk for death was higher in patients with advanced WHO stage, low CD4 count, low Hgb, low BMI, and concomitant TB infection. Intensive case management is recommended for patients with the prognostic factors. Optimal immunologic and weight recoveries in the first 6 months suggest increased effort to retain patients in care at this period.


HIV/AIDS; Mortality; HAART; Survival; Predictors of death; Antiretroviral therapy; Ethiopia


According to the 2012 UNAIDS report, there are an estimated 34 million People Living with HIV (PLHIV) worldwide, Sub-Saharan Africa (SSA) accounting for 69%, with nearly 1 in every 20 adults (4.9%) living with HIV; around 1.7 million people died from AIDS-related causes worldwide, 70% occurred in SSA [1]. Ethiopia is one of the hardest hit sub-Saharan African countries by the HIV pandemic. By the end of 2012, there were 759,268 people living with HIV; 41,444 deaths from AIDS-related causes and 20,158 new HIV infections [2]. For 2007, the estimated life expectancy was 52.5 years, with 3.9 years lost to AIDS [3].

In January 2005, the FDRE Ministry of Health (MoH) launched the free ART rollout program. By the end of 2011 there were 249,174 patients on treatment, making the ART coverage for adult population of PLHIV 86% [4]. The introduction of HAART witnessed a decrease in AIDS-defining opportunistic infections, a decline in AIDS related mortalities, and improved survival of PLHIV. Despite increased availability of ARV and promising efficacy reported from ART programs in resource-limited settings, mortality has been high particularly the first few months after initiating ART [5,6].

Reporting treatment outcomes of patients enrolled in ART programs is important to demonstrate program effectiveness and justify continued funding, while assessment of factors associated with outcomes can help to identify opportunities for program improvement [7]. Few studies have reported baseline socio-demographic and clinical factors in predicting survival after ART initiation [8-10]. However, there are no studies describing mortality on ART and its associated factors over longer follow up periods. Therefore, this study determines factors associated with survival and progressive immunologic and weight changes among adult PLHIV receiving ART in Somali region, Ethiopia.


Study setting

The study was conducted at Kharamara hospital, in Jijiga town from March to May 2013. Jijiga, the administrative capital of Somali region, is located 614 km to the east of Addis Ababa, Ethiopia’s capital. The hospital provides general outpatient and inpatient services, surgical and obstetric emergency, and regional referral hospital for ophthalmologic service. In the comprehensive HIV care and treatment service at the hospital, there are 9,208 patients enrolled, of which 1,501 ever-started ART, and 1,432 currently on ART.

Study design

A retrospective cohort study was conducted to assess survival and determinants of mortality among PLHIV receiving antiretroviral therapy. A total of 784 PLHIV aged ≥15 years, initiating ART at Kharamara hospital between December 1, 2007 and December 31, 2011 were included in the study. The independent variables were sociodemographic characteristics, baseline clinical, laboratory and ART information. The main outcome measure in the study was follow-up time till death. The second outcome measures were median changes in CD4 count and weight.


The source population was adult HIV/AIDS patients who started ARV and were on follow up at the ART clinic during the study period. Patients who initiated treatment outside Kharamara hospital, and women who were pregnant and lactating mothers on Prevention of Mother to Child Transmission (PMTCT) were excluded. The sample size was determined by taking the mortality rates in two groups of PLHIV on ART based on their WHO clinical stage as exposure status. The mortality rate among exposed (WHO stage IV) is 0.3% and among non-exposed (WHO stage II-III), 0.1% [10]. The study participants were randomly selected using patients’ unique identification number and were retrospectively followed for additional 60 months until December 31, 2012.

Data collection and quality control

To compile the required information a data collection form was developed from the national ART intake and follow-up forms. The data were collected by reviewing pre-ART register, ART intake form, laboratory request form, monthly cohort form, and follow up form. The most recent laboratory results before starting ART were used as a baseline value. If there were no pre-treatment laboratory tests, results obtained within one month of ART initiation were used as baseline. If two results were obtained within a month, their mean would be used.

The data was collected by two experienced ART nurses who were trained on comprehensive HIV care and who are working in the ART clinic at Kharamara hospital. A supervisor supervised the data collection process. The investigator oversaw the overall process. All completed data collection forms were examined for completeness, consistency and clarity during data management, storage, and analysis.

Study variable and measurements

The main outcome variable in this study was death from all causes obtained from patients’ medical records in the hospital, registrations at the ART clinic reported by adherence supporters. Patients were censored on the date of any one of the following events, whichever occurred first: if lost to follow-up, if transferred to another health facility, or if alive at the end of follow up. Additional home visits and phone calls were made by two adherence supporters to confirm outcome status of lost to follow-up patients at the time of censoring.

All HIV-positive persons were routinely screened for TB at enrolment, and during each follow-up visit. The national TB/HIV guidelines recommend administration of INH Preventive Therapy (IPT) to HIV-infected persons after exclusion of active TB. The recommended dose of INH for adults is 300mg/day for duration of six months [11]. Diagnosis of active TB infection in HIV-positive patients was made based microscopic results for Acid-Fast Bacilli (AFB) [12] as: TB-positive (at least 1 initial sputum smear positive for AFB by direct microscopy, or 1 initial sputum smear positive for AFB by concentrated method) and TB-negative (3 initial smears negative for AFB).

Adherence to ART was evaluated by the percentage of missed doses documented by the ART physician [13], and was ranked as good (if <5% (<2 doses of 30 doses or <3 dose of 60 doses), fair (if between 5−15% (3-5 doses of 30 doses or 3−9 doses of 60 doses) or poor (if >15% (>6 doses of 30 doses or >9 dose of 60 dose) as documented by ART physician.Body mass index (BMI) was used to assess patients’ nutritional status. Established cutoff values for BMI were used [14]: normal (BMI ≥ 18.5 kg/m2), and malnutrition (BMI<18.5 kg/m2). Anemia was defined as a hemoglobin level of <12 g/dL for women and <13 g/dL for men [15], and was classified as mild (hemoglobin 10–1.9 g/dL for women and 10–12.9 g/dL for men), moderate (hemoglobin 8–9.9 g/dL) or severe (hemoglobin<8 g/dL).

Data analysis

Data exploration was carried out to check for any inconsistencies, coding error, out of range, and missing values and appropriate corrections were made. Descriptive analyses of the continuous and categorical data describing the cohort’s characteristics at baseline and during followup were made. The outcomes of each patient were dichotomized into censored or dead. Kaplan-Meier model was be used to assess survival functions stratified by baseline and follow up variables, and the log-rank test was used to assess statistical difference among groups (for equality of survival distributions). Multicollinearity was excluded using Spearman's correlation coefficient with a cutoff at 0.5. Cox-proportional hazards model was used to identify prognostic factors of death and variables significant at P<0.25 level in the bivariate analysis were included in the final multivariable model. All analyses were conducted using SPSS version 16.0 for windows (SPSS® Inc., Chicago, IL, USA).


The study cohort included 784 patients with a mean age of 34 (SD±10). Out of the total study population, 485 (58.4%) were females. Three hundred twenty five (41.5%) were married and 455 (58%) had dependent children at home. Four hundred eighty seven (62.1%) had at least completed primary education, and 359 (45.8%) had no occupation. The majority 431 (55%) had good ART adherence (Table 1).

Variables Total (N, %) Dead (N, %) Active (N, %) Log-rank P
Sex       0.019
Male 326 (41.6%) 46 (52.9%) 280 (40.2%)
Female 458 (58.4%) 41 (47.1%) 417 (59.8%)
Age category       0.249
15-24 108 (13.8%) 6 (6.9%) 102 (14.6%)
25-34 327 (41.7%) 41 (47.1%) 102 (14.6%)
35-44 229 (29.2%) 25 (28.7%) 204 (29.3%)
45+ 120 (15.3%) 15 (17.2%) 105 (15.1%)
Religion       0.714
Muslim 319 (40.7%) 35 (11.0%) 284 (89.0%)
Orthodox 438 (55.9%) 50 (11.4%) 388 (88.6%)
Protestant 27 (3.4%) 2 (7.4%) 25 (92.6%)
Marital status       0.002
Married 325 (41.5%) 27 (31.0%) 298 (42.8%)
Single 115 (14.7%) 24 (27.6%) 91 (13.1%)
Separated 27 (3.4%) 1 (1.1%) 26 (3.7%)
Divorced 226 (28.8%) 26 (29.9%) 200 (28.7%)
Widowed 91 (11.6%) 9 (10.3%) 82 (11.8%)
Educational status       0.000
No education 297 (37.9%) 48 (55.2%) 249 (35.7%)
Primary 217 (27.7%) 27 (31.0%) 190 (27.3%)
Secondary 207 (26.4%) 10 (11.5%) 197 (28.3%)
College/Above 63 (8.0%) 2 (2.3%) 61 (8.8%)
Dependent children       0.889
Yes 455 (58.0%) 52 (59.8%) 403 (57.8%)
No 329 (42.0%) 35 (40.2%) 294 (42.2%)
ART Adherence*       0.000
Good 431 (55.0%) 36 (41.4%) 395 (56.7%)
Fair 431 (55.0%) 20 (23.0%) 157 (22.5%)
Poor 176 (22.4%) 31 (35.6%) 145 (20.8%)

Table 1: Socio-demographic characteristics of adult PLHIV receiving ART in Somali region, Ethiopia [N=784], May 2013

At the time of ART initiation, 455 (58.0%) were in WHO clinical stage III&IV and 242 (30.9%) had an ambulatory functional status. Among the study participants, 449 (57.3%) had a BMI<18.5 Kg/m2 and 311 (39.7%) developed active TB infection. At ART initiation time, 221 (28.2%) were receiving d4T/3TC/NVP ART regimen. With regard to chemoprophylaxis, the majority 658 (83.9%) were given cotrimoxazole and only 61 (7.8%) received Isoniazid (INH) preventive therapies. The mean (IQR) weight, CD4 count and hemoglobin of the cohort were 50kg (44-56), 150 cells /μL (102-196) and 11.4 g/dL (10-13) respectively (Table 2).

Variables Total (N, %) Dead (N, %) Active (N, %) Log-rank P
Functional status       0.000
Working 434 (55.4%) 12 (13.8%) 422 (60.5%)
Ambulatory 242 (30.9%) 37 (42.5%) 205 (29.4%)
Bedridden 108 (13.8%) 38 (43.7%) 70 (10.0%)
WHO staging       0.000
Stage I & II 329 (42.0%) 10 (11.5%) 319 (45.8%)
Stage III 327 (41.7%) 38 (43.7%) 289 (41.5%)
Stage IV 128 (16.3%) 39 (44.8%) 89 (12.8%)
BMI for age       0.000
≥18.5 Kg/m2 335 (42.7%) 23 (26.4%) 312 (44.8%)
< 18.5 Kg/m2 449 (57.3%) 64 (73.6%) 385 (55.2%)
ART regimen       0.429
d4T/3TC/NVP 221 (28.2%) 25 (28.7%) 196 (28.1%)
d4T/3TC/EFV 78 (9.9%) 7 (8.0%) 71 (10.2%)
AZT/3TC/NVP 202 (25.8%) 25 (28.7%) 177 (25.4%)
AZT/3TC/EFV 50 (6.4%) 5 (5.7%) 45 (6.5%)
TDF/3TC/EFV 118 (15.1%) 10 (11.5%) 108 (15.5%)
TDF/3TC/NVP 115 (14.7%) 15 (17.2%) 100 (14.3%)
Cotrimoxazole       0.032
Given 658 (83.9%) 66 (75.9%) 592 (84.9%)
Not given 126 (16.1%) 21 (24.1%) 105 (15.1%)
INH Given       0.000
Given 61 (7.8%) 20 (23.0%) 41 (5.9%)
Not given 723 (92.2%) 67 (77.0%) 656 (98.3%)
TB co-infected       0.015
Yes 311 (39.7%) 45 (51.7%) 266 (38.2%)
No 473 (60.3%) 42 (48.3%) 431 (61.8%)
Weight (Kg) ‡ 49.9 (44−56) 43.8 (37−50) 50.7 (45−56) 0.000
CD4 count (cells/ μL) ‡ 150 (102−196) 72 (31−99) 160 (116−206) 0.000
Hemoglobin (g/dL) ‡ 11.4 (10.0−13.0) 9.9 (7.9−11.3) 11.6 (10.3−13.1) 0.000

Table 2: Clinical and laboratory markers of adult PLHIV receiving ART in Somali region, Ethiopia [N=784], May 2013

Follow up

A total of 87 (11.1%) patients died during the five year followup period, with majority of deaths 49(56.3%) occurring in the first 3 months (HR: 0.022). One hundred fifty seven (20.0%) patients were transferred to other facility and 193 (24.6%) were lost-to-follow up. The remaining 344 (43.9%) were active until the last censoring date. The median survival time for event (death) was 20.7 months (IQR, 17.5- 22.6). The overall mortality rate in the cohort during the 1,608 personyears of observation (PYO) was 5.15/100 PYO (95% CI: 4.73-6.37). The estimated mortality was 8.4%, 9.8%, 11.3%, 12.7% and 14.1% at 6, 12, 24, 36 and 48 months respectively (Figure 1).

Predictors of mortality

In bivariate Cox regression analysis, sex, marital status, education level, functional status, WHO clinical stage, BMI, CD4 count, Anemia, cotrimoxazole prophylaxis, INH prophylaxis, TB co-infection, and ART adherence were all associated with survival (P<0.05).

In the multivariate Cox regression analysis, the independent, significant predictors of mortality in PLHIV on ART at Kharamara hospital were single marital status (AHR: 2.31; 95%CI: 1.18-4.50), a bedridden functional status (AHR: 5.91; 95%CI: 2.87-12.16), advanced WHO stage (AHR: 7.36; 95%CI: 3.17-17.12), BMI<18.5 Kg/m2 (AHR: 2.20; 95%CI: 1.18-4.09), CD4 count <50 cells/μL (AHR: 2.70; 95%CI: 1.26-5.80), severe anemia (AHR: 4.57; 95%CI: 2.30-9.10), and TB coinfection (AHR: 2.30; 95% CI: 1.28-4.11) (Table 3).

Variables Crude HR (95% CI) P value AHR (95% CI) Pvalue
Marital status        
Married 1 - 1 -
Single 2.69 (1.55, 4.66) 0.001 2.31 (1.18, 4.50) 0.015
Separated 0.40 (0.05, 2.94) 0.367 0.13 (0.014, 1.21) 0.073
Divorced 1.41 (0.82, 2.41) 0.215 1.47 (0.80, 2.71) 0.215
Widowed 1.15 (0.54, 2.44) 0.719 1.27 (0.56, 2.86) 0.566
Educational status        
No education 5.66 (1.38, 23.29) 0.016 4.73 (1.07, 22.40) 0.038
Primary 4.26 (1.01, 17.91) 0.048 3.83 (0.80, 18.30) 0.082
Secondary 1.54 (0.34, 7.05) 0.575 2.43 (0.50, 12.01) 0.281
College/Above 1 - 1 -
Functional status        
Working 1 - 1 -
Ambulatory 6.16 (3.21, 11.82) 0.000 2.12 (1.05, 4.26) 0.035
Bedridden 15.42 (8.05, 29.53) 0.000 5.91 (2.87, 12.16) 0.000
WHO staging        
Stage I&II 1 - 1 -
Stage III 5.28 (2.60, 10.71) 0.000 4.00 (1.83, 8.74) 0.000
Stage IV 16.22 (7.93, 33.20) 0.000 7.36 (3.17, 17.12) 0.000
BMI for age        
≥18.5 Kg/m2 1 - 1  
< 18.5 Kg/m2 2.27 (1.41, 3.66) 0.001 2.20 (1.18, 4.09) 0.013
CD4 category        
≥ 200 1 - 1 -
125-200 3.87 (2.05, 7.27) 0.000 1.33 (0.65, 2.72) 0.440
50-125 5.62 (3.04, 10.41) 0.000 2.24 (1.08, 4.65) 0.031
< 50 17.36 (9.96, 30.28) 0.000 2.70 (1.26, 5.80) 0.011
Normal 1 - 1 -
Mild 1.16 (0.56, 2.42) 0.695 1.16 (0.52, 2.60) 0.724
Moderate 3.27 (1.69, 6.32) 0.000 2.90 (1.36, 6.16) 0.006
Severe 8.01 (4.53, 14.17) 0.000 4.57 (2.30, 9.10) 0.000
TB co-infected        
Yes 2.21 (1.35, 3.62) 0.002 2.30 (1.28, 4.11) 0.005
No 1 - 1 -

Table 3: Predictors of mortality among adult PLHIV receiving ART in Somali region, Ethiopia [N=784], May 2013

Weight and CD4 change during the follow-up

Weight and CD4 recovery were used as supplementary indicators for comprehensive treatment outcomes. At the start of ART, the median weight of the cohort was 50.0 Kg. During the follow-up period, the median weight (IQR) at 6, 12, 24, 36, 48 and 60 months were 54 (48- 61), 55 (48-64), 56 (50-64), 56 (49-64), 57 (50-65) and 57 (50-64), Kg., respectively (Figure 2). Similarly, the median CD4 count at baseline was 146 cells/μL. In the follow-up period, the median CD4 count (IQR) changed to 258 (172-369), 286 (201-406), 351 (246-506), 389 (270-549), 405 (302-565) and 567 (390-770) at 6, 12, 24, 36, 48 and 60 months, respectively (Figure 3). During the follow-up period, 123 patients had their CD4 count declined to below or equal to the baseline values yielding an immunologic treatment failure rate of 7.84/100 PYO (95% CI:6.89-8.81).


In this historical longitudinal study, there were 87 deaths in 1,608 PYO, yielding an incidence density of 5.15/100 PYO (95%CI: 4.73-6.37). The independent predictors of mortality include single marital status, being illiterate, bedridden functional status, advanced WHO status, low BMI, low CD4 count, severe anemia and TB co-infection.The estimated survival probability of the cohort at 6, 12, 24, 36, 48 and 60months was 91.6%, 90.2%, 88.7%, 87.3%, 85.9% and 84.8%, respectively. This shows a better survival compared to other studies in Africa. According to a study in a Malawian cohort, the probability of being alive on ART at 6, 12 and 18 months was 89.8%, 83.4% and 78.8% respectively [16]. On the other hand, the death rate was comparable to most studies, especially, in the first six months [6,8,9]. This might be explained by the fact that most of the patients in this study had advanced disease status (78% had CD4<200 cells/μL and 58% were in WHO stage III & IV).

Patients who were illiterate had high risk of mortality compared to those with college education or above (AHR: 4.73; 95%CI: 1.07-22.40). A study conducted in Ethiopia also found a strong association between level of education and survival [17]. Single patients had a higher risk for death compared to married patients (AHR: 2.31; 95%CI: 1.18- 4.50). This difference might be due to married patients’ psychological preparedness to seek partners’ and social support, conceive the facts, and adhere to ART [18].

The result from this study shows patients with a CD4 count of <50 cells/μL have a higher risk of mortality (AHR: 2.70; 95% CI: 1.26-5.80) compared to those with a CD4 count of ≥ 200 cells/μL. Majority of previous studies also found twice or more risk of mortality in patients with lower CD4 count compared to those with a CD4 count of ≥ 200 cells/μL [5,17,19].

Patients with severe anemia were 4.57 more at risk of death compared to those with normal levels. In a study from Tanzania, patients with severe anemia were 15 times higher at risk of dying during the first year on ART compared to those with a normal hemoglobin level [6]. Other studies have also indicated patients with low hemoglobin level (<10 mg/dL) had increased risk of death [5,9,20]. Although there is no concrete evidence on casual association between anemia and mortality, the incidence of anemia increased with progression of HIV disease [19]. In this study also, severe anemia was associated with an advanced WHO stage (24.2% in Stage IV vs. 8.8% in stage I&II). One of the most important side effects of AZT is myelotoxicity leading to severe anemia [20]. In this cohort, severe anemia in patients taking AZT was higher (46.7%) among the dead compared to those censored (8.8%).

In the current study, the risk of death in patients with a BMI<18.5 Kg/m2 was more than two times higher (AHR: 2.20; 95%CI: 1.18-4.09) compared to those with a BMI ≥ 18.5 kg/m2. Study conducted in rural Malawi showed individuals who were severely malnourished (BMI<16 kg/m2) had six times higher risk of dying in the first three months than those with a normal nutritional status [21]. BMI is an indicator of patient nutritional status but may also be influenced by late-stage AIDS conditions, such as wasting syndrome and opportunistic infections, or by progression of the HIV itself [22]. In the current cohort, there was a significant difference in mean BMI between TB positive patients (18.10; 95%CI: 17.66-18.54) and TB negative ones (18.77; 95%CI: 18.40-19.14), and also, between WHO stage I&II (19.68; 95%CI: 19.24-20.13) and WHO stage IV (17.13; 95%CI: 16.49-17.77).

TB co-infection at baseline or later was also associated with increased risk of mortality (AHR: 2.30; 95%CI: 1.28-4.11). Study conducted in Uganda shows, after adjusting for a history of HIV related infections, the overall relative hazard for death associated with tuberculosis was 1.81 (95%CI: 1.24-2.65) [23]. Manosuthi et al. also showed patients who delayed ART for >6 months after TB diagnosis had a higher mortality rate than those who initiated ART<6 months after TB diagnosis [24]. Other studies in Ethiopia have also showed the similar relationship [10,25]. High mortality in patients living with HIV/ AIDS in poor countries was linked to concomitant TB infection [20]. This may be because TB is the leading cause of death worldwide, and the virulence of the mycobacterium increases in HIV infected patients, where the host’s immune system is suppressed, enabling it to establish infection very easily [26].

Different studies conducted in African countries, including Ethiopia, have shown a progressive change in CD4 count and weight after initiation of ART [9,27]. These studies showed that the most significant increment in the median CD4 count occurred in the first six months of ART which is also the case in the current study; wherein a 76.2% increase from baseline median level was observed in the first six months. The recovery in weight also showed a similar progress in the first six months (8% gains). However, the change in median CD4 and median weight in subsequent months was minimal, with an average gain of 17% and 1.4%, respectively. In addition, the immunologic recovery was much slower in patients with baseline AIDS defining disease [23].

This cohort study has provided information on prognostic factors for death in adult PLHIV receiving ART. The findings can be essential inputs in redesigning clinical management of high risk patients and ultimately improving their survival and quality of living. In addition, this study will provide ample information for future, more focused, prospective studies, especially on outcome status and underlying causes of patients lost to follow-up.

Limitations of the Study

The study has few limitations. Inclusion of only patients with complete records of baseline information during data collection might have made selection bias possible.As data used in this study was retrospective, there were few incomplete follow-up records (due to patients’ missed clinical visits), and we were unable to include some variables (e.g. CD4, Hgb, etc.) as time-dependent covariates in our analysis.All deaths were considered as AIDS related for lack of available records on the causes of death.


Improved survival was observed in patients taking ART in Somali region of Ethiopia. However, the risk for death was higher in patients with bed-ridden functional status, advanced WHO stage, low CD4 count, severe anemia, low BMI, and concomitant TB infection. Intensive clinical and nutritional rehabilitation is recommended during the earliest follow up periods on ART for patients with these prognostic factors. Providing follow-up screening and chemoprophylaxis for to patients with a history of TB infection on ART is insurmountable in deterring the infection and decreasing mortality. Optimal immunologic and weight recoveries occurred in the first six months indicating the need for increased attention and clinical management for patients with higher risk for death during this crucial period of recovery.


We would like to thank and appreciate all patients who participated in the study. We are indebted to the staff at Kharamara hospital ART clinic, especially, Azenegash Mekonen and Samrawit Mekonen for their invaluable contributions in collection and quality control of data. We are grateful to the adherence supporters Abun Dube and Aynalem Bekele who carried out home visits to ascertain patients’ final outcome status. We are also grateful to Somali Regional Health Bureau for facilitating conditions while carrying out this study. We would like to extend our heartfelt gratitude and appreciations to Tiringo Nigusse for her financial support to this project.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

  • 5th International Conference on HIV/AIDS, STDs and STIs
    November 13-14, 2017 Las Vegas, Nevada, USA

Article Usage

  • Total views: 11822
  • [From(publication date):
    July-2014 - Sep 24, 2017]
  • Breakdown by view type
  • HTML page views : 7974
  • PDF downloads :3848

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version